Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
2.740
-0.070 (-2.49%)
At close: Oct 13, 2025, 4:00 PM EDT
2.740
0.00 (0.00%)
After-hours: Oct 13, 2025, 4:10 PM EDT
Artiva Biotherapeutics Revenue
In the year 2024, Artiva Biotherapeutics had annual revenue of $251.00K, down -99.25%.
Revenue (ttm)
$251.00K
Revenue Growth
-99.25%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
89
Market Cap
66.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 251.00K | -33.24M | -99.25% |
| Dec 31, 2023 | 33.49M | 28.56M | 579.21% |
| Dec 31, 2022 | 4.93M | 2.93M | 146.30% |
| Dec 31, 2021 | 2.00M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ARTV News
- 7 weeks ago - Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 - GlobeNewsWire
- 2 months ago - Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewsWire
- 4 months ago - Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewsWire
- 6 months ago - Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - GlobeNewsWire
- 6 months ago - Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - GlobeNewsWire
- 7 months ago - Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire